The Quotient Therapeutics team (L-R): acting COO Scott Hayton, head of genetics and target discovery Caroline Fox, president Jacob Rubens, head of platform Simon Brunner, and CEO Geoff von Maltzahn (Credit: Quotient Therapeutics)

Flag­ship launch­es first UK-based start­up to un­cov­er genes that make cells vul­ner­a­ble or re­sis­tant to dis­ease

A new biotech start­up be­lieves that ge­net­ic di­ver­si­ty found among the tril­lions of cells that com­prise an in­di­vid­ual per­son could hold the keys to new clues for treat­ing or pre­vent­ing dis­ease.

Flag­ship Pi­o­neer­ing, a life sci­ences in­vest­ment firm that builds its own biotech star­tups, an­nounced an ini­tial $50 mil­lion com­mit­ment to Quo­tient Ther­a­peu­tics at its launch from stealth on Tues­day morn­ing.

In a first for Flag­ship, which usu­al­ly keeps its com­pa­nies close to its home base around Boston, Quo­tient launched with the ma­jor­i­ty of its em­ploy­ees in Cam­bridge, UK. A spokesper­son for Flag­ship said the life sci­ences firm’s UK of­fices will of­fi­cial­ly open next week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.